TLPH_OUT_1 [2025-04-02 17:59:56 -0400] 2925 Bytes | 828 tokens | Cum: 828 tkns (10.35% of 8k)
==========================================================================

We need a winner today and it's already 5:59:55 PM on Wed Apr 02, 2025 -0400 ... So let's find out if Talphera (TLPH) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 0.6199 up from 0.53. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Talphera (TLPH)
IPO: 2011-02-11 (14 Years Ago)
Market Cap: $9,025,486
Shares Outstanding: 17,030,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Here's the first list of news for Talphera:

C1 - Apr-01-25 03:03AM - Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights
C2 - Mar-31-25 06:33PM - Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript
C3 - Mar-31-25 06:33PM 04:05PM - Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
C4 - Mar-31-25 06:33PM 08:30AM - Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million
C5 - Mar-26-25 04:38PM - Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025
C6 - Jan-14-25 08:30AM - Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
C7 - Nov-24-24 07:27PM - Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
C8 - Nov-14-24 02:14AM - Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges

Prior AI Reports for TLPH:
1. 2025-04-01 – Score: 15 – Target: 0.5742 – Highs: – / – / –
troubled-waters-ahead-pervasive-negative-indicators-for-company

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Talphera (TLPH)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TLPH_OUT_3 [2025-04-02 18:00:01 -0400] 1099 Bytes | 316 tokens | Cum: 1146 tkns (14.32% of 8k)
==========================================================================

Showing C4 (chunk 1 of 14): C4:
**Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million**
Date: Mar-31-25 06:33PM 08:30AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/talphera-announces-agreement-with-the-fda-to-reduce-the-nephro-crrt-study-size-to-70-patients-from-166-and-a-private-placement-financing-priced-at-the-market-of-up-to-14-8-million-302415309.html

The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled

Talphera believes the NEPHRO CRRT study should be completed by the end of 2025

Existing investors, Nantahala Capital and Rosalind Advisors led the capital commitment priced at-the-market as defined by Nasdaq rules

$4.925 millionin gross

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_5 [2025-04-02 18:00:02 -0400] 903 Bytes | 271 tokens | Cum: 1532 tkns (19.15% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T07:03:18Z - Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights...
A2 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A3 - 2025-03-31T20:52:26Z - Talphera: Q4 Earnings Snapshot...
A4 - 2025-03-31T20:30:19Z - Talphera: Q4 Earnings Snapshot - WTOP News...
A5 - 2025-03-31T20:05:00Z - Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TLPH_OUT_7 [2025-04-02 18:00:10 -0400] 1098 Bytes | 325 tokens | Cum: 1859 tkns (23.24% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights**Date: 2025-04-01Source: {'uri': 'ca.finance.yahoo.com', 'dataType': 'news', 'title': 'Yahoo! Finance'}URL: https://ca.finance.yahoo.com/news/talphera-inc-tlph-q4-2024-070318456.htmlPrivate Placement Investment: Agreement for up to $14.8 million in gross proceeds.

Cash Position: $8.9 million in cash as of December 31, 2024.

Operating Expenses: Combined R&D and SG&A expenses for Q4 2024 totaled $3 million, down from $4.6 million in Q4 2023.

Excluding Stock-Based Compensation: R&D and SG&A expenses were $2.8 million for Q4 2024, compared to $4.3 million for Q4 2023.

Projected Cash Operating Expenses for 2025: Expected to be in the range of $18 million to $19 million.

NEPHRO CRRT Study Size Reduction: FDA approved reduction from 166 patients to 70, maintaining 90% power for the primary en

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_9 [2025-04-02 18:00:17 -0400] 1098 Bytes | 266 tokens | Cum: 2320 tkns (29.00% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): dpoint.

Enrollment Ready Sites: Increased to eight, with plans to add five more by mid-year 2025.

Warning! GuruFocus has detected 2 Warning Signs with TLPH.

Release Date: March 31, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Talphera Inc (NASDAQ:TLPH) secured a private placement investment agreement for up to $14.8 million, providing capital to potentially complete the NEPHRO CRRT study by the end of 2025.

The FDA approved a reduction in the NEPHRO trial size from 166 to 70 patients, maintaining a 90% power for the primary endpoint, which accelerates the study timeline.

Talphera Inc (NASDAQ:TLPH) received FDA approval for significant protocol changes, including broader inclusion criteria, which are expected to enhance patient enrollment.

The company has successfully added new clinical study sites with

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_11 [2025-04-02 18:00:18 -0400] 1098 Bytes | 238 tokens | Cum: 2680 tkns (33.50% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): higher CRRT volumes, increasing the potential for faster patient enrollment.

Talphera Inc (NASDAQ:TLPH) has reduced operating expenses, reflecting a focused approach on completing the NEPHRO study efficiently.

Negative Points

The NEPHRO CRRT study's completion is contingent on achieving specific patient enrollment milestones and stock price conditions for the release of additional financing tranches.

There is a risk of delays in site activation and patient enrollment, which could impact the study timeline.

The company faces commercial risks despite the potential advantages of Niyad over current anticoagulants like heparin and citrate.

Talphera Inc (NASDAQ:TLPH) may need to deactivate unproductive clinical sites if they do not meet enrollment expectations.

The reliance on new clinical sites and protocol changes introduces uncertainty in achieving the projected study completion by t

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_13 [2025-04-02 18:00:18 -0400] 392 Bytes | 107 tokens | Cum: 2789 tkns (34.86% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-01-31T13:17:10Z - Why Sintx Technologies Shares Are Trading Higher By Over 39%; Here Are 20 Stocks Moving Premarket

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TLPH_OUT_15 [2025-04-02 18:00:24 -0400] 1100 Bytes | 300 tokens | Cum: 3091 tkns (38.64% of 8k)
==========================================================================

Showing B1 (chunk 1 of 2): B1:
**Why Sintx Technologies Shares Are Trading Higher By Over 39%; Here Are 20 Stocks Moving Premarket**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/01/36865230/why-sintx-technologies-shares-are-trading-higher-by-over-39-here-are-20-stocks-moving-premarketShares of Sintx Technologies, Inc. (NASDAQ: SINT) rose sharply in today’s pre-market trading after the company announced its subsidiary Technology Assessment & Transfer entered into a Cooperative Research and Development agreement with the U.S. Army Combat Capabilities Development Command Army Research Laboratory.
Sintx Technologies shares jumped 39.3% to $0.3393 in pre-market trading
Here are some other stocks moving in pre-market trading.
Gainers

Revelation Biosciences, Inc. (NASDAQ: REVB) gained 50.3% to $11.95 in pre-market trading after dipping around 39% on Tuesday.
Minim, Inc. (NASDAQ: MINM) sh

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_17 [2025-04-02 18:00:24 -0400] 1100 Bytes | 282 tokens | Cum: 3476 tkns (43.45% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond

On March 31, 2025, Talphera, Inc. (the Company) issued a press release announcing its financial results for the three and twelve months ended December 31, 2024 and providing a corporate update (the Release). A copy of the ...

S2 - 2025-03-31 10-K Item 7. Management s Discussion and Analysis of Fin Cond and Results of Oper

The following discussion and analysis should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-...

S3 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond

On March 31, 2025, Talphera, Inc. (the Company) issued a press release announcing its financial results for the three and twelve months ended December 31, 2024 and providing a corporate update (the Release). A copy of the ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TLPH_OUT_19 [2025-04-02 18:00:25 -0400] 1098 Bytes | 245 tokens | Cum: 3723 tkns (46.54% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-K.

The following discussion and analysis covers our financial condition and results of operations for the year ended December 31, 2024, including year-over-year comparisons versus the year ended December 31, 2023, as reported in our Annual Report on Form 10-K for the year ended December 31, 2023. This discussion and analysis as well as other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions, and projections. Our actual results could differ materially from those discusse

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_21 [2025-04-02 18:00:30 -0400] 1098 Bytes | 258 tokens | Cum: 3983 tkns (49.79% of 8k)
==========================================================================

Showing S2 (chunk 2 of 6): d in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A Risk Factors of this Annual Report on Form 10-K.

Overview

We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Our product development portfolio features Niyad (a regional anticoagulant for the dialysis circuit), LTX-608 (a nafamostat formulation for direct IV infusion) that we intend to develop for one or more of the following indications: disseminated intravascular coagulation, or DIC, acute respiratory distress syndrome, or ARDS, acute pancreatitis, or as an anti-viral treatment, and two ready-to-use pre-filled syringe product candidates (Fedsyra and phenylephrine).

Our strategy is focused on developing, obtaining

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TLPH_OUT_23 [2025-04-02 18:00:43 -0400] 5159 Bytes | 1553 tokens | Cum: 5638 tkns (70.47% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+----------------------+-------------------------+-------------------------+
| Volume: 41,134 | Perf Month: 8.18% | Option/Short: Yes / Yes | Sales Y/Y TTM: -100.00% |
+--------------------+----------------------+-------------------------+-------------------------+
| Avg Volume: 69.46K | Perf Quarter: 8.95% | Short Float: 0.62% | ROE: -117.65% |
+--------------------+----------------------+-------------------------+-------------------------+
| Rel Volume: 0.59 | Index: - | Short Ratio: 1.50 | ROI: -162.53% |
+--------------------+----------------------+-------------------------+-------------------------+
| RSI (14): 49.48 | Market Cap: 9.97M | Short Interest: 0.10M | Sales Surprise: - |
+--------------------+----------------------+-------------------------+-------------------------+
| ATR (14): 0.07 | Shs Outstand: 17.03M | Beta: -0.16 | EPS Surprise: 57.58% |
+--------------------+----------------------+-------------------------+-------------------------+
| SMA20: 0.73% | Shs Float: 16.67M | Sales Q/Q: -100.00% | P/E: - |
+--------------------+----------------------+-------------------------+-------------------------+
| SMA50: -4.05% | Inst Own: 29.21% | Sales past 5Y: - | Earnings: Mar 31 AMC |
+--------------------+----------------------+-------------------------+-------------------------+
| SMA200: -24.93% | Insider Own: 2.11% | Employees: 13 | |
+--------------------+----------------------+-------------------------+-------------------------+
| Perf Week: -8.89% | Insider Trans: 4.52% | Debt/Eq: 0.00 | |
+--------------------+----------------------+-------------------------+-------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: TALPHERA, INC. (TLPH) by Dasu Badri N (Chief Engineering Officer) on 2025-02-14
- Common Stock: 2644 shares at $0.67 (D)

Inside Trans: TALPHERA, INC. (TLPH) by ASADORIAN RAFFI (Chief Financial Officer) on 2025-02-14
- Common Stock: 3245 shares at $0.67 (D)

Inside Trans: TALPHERA, INC. (TLPH) by Angotti Vincent J. (CHIEF EXECUTIVE OFFICER) on 2025-02-14
- Common Stock: 10575 shares at $0.67 (D)

Inside Trans: TALPHERA, INC. (TLPH) by Angotti Vincent J. (CHIEF EXECUTIVE OFFICER) on 2025-02-10
- Common Stock: 3515 shares at $0.6299 (D)
- Common Stock: 3517 shares at $0.62 (D)

Inside Trans: TALPHERA, INC. (TLPH) by ASADORIAN RAFFI (Chief Financial Officer) on 2025-02-10
- Common Stock: 1059 shares at $0.6299 (D)
- Common Stock: 1060 shares at $0.62 (D)

Inside Trans: TALPHERA, INC. (TLPH) by Dasu Badri N (Chief Engineering Officer) on 2025-02-10
- Common Stock: 879 shares at $0.6299 (D)
- Common stock: 880 shares at $0.62 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -3353000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.583
Average Volume: 46941.57
30-Day High: 0.6437
30-Day Low: 0.495

[Detailed Financials: Q3 2024]
- Total Assets: $21,014,000.0
- Total Liabilities: $11,373,000.0
- Total Equity: $9,641,000.0
- Current Assets: $12,195,000.0
- Current Liabilities: $2,762,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.13

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-2,306,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $24,856,000.0
- Total Liabilities: $12,126,000.0
- Total Equity: $12,730,000.0
- Current Assets: $16,037,000.0
- Current Liabilities: $3,274,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.15

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $1,301,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TLPH_OUT_25 [2025-04-02 18:00:45 -0400] 676 Bytes | 167 tokens | Cum: 6134 tkns (76.68% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TLPH_IN_27 [2025-04-02 18:00:45 -0400] 126 Bytes | 29 tokens | Cum: 6191 tkns (77.39% of 8k)
==========================================================================

====================================
[2025-04-02 18:00:45] # Analysis Completed
Elapsed Time: 49.75 seconds